Short answer
REGENXBIO Inc. (RGNX) filed an 8-K current report with the SEC on September 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $39.0 million payment from Sarepta due within 10 days of settlement effectiveness.
REGENXBIO Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $39.0 million payment from Sarepta due within 10 days of settlement effectiveness
- Settlement resolves all patent litigation involving ELEVIDYS and REGENXBIO’s 617 and 274 patents
- REGENXBIO releases current infringement claims and covenants not to sue over AAVrh74-based products
- Agreement limits future claims involving ELEVIDYS and AAVrh74 capsid patents, reducing litigation upside and risk
- Settlement agreement expected in REGENXBIO’s September 30, 2026 Form 10-Q
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other REGENXBIO Inc. 8-K filings
Get the next RGNX 8-K as it lands
Follow RGNX for push alerts, or ask the research agent what this filing means.